CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
June 02, 2022 20:10 ET
|
Aptose Biosciences, Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 ...
Aptose Presents Highlights from Corporate Update and KOL Event
June 02, 2022 17:30 ET
|
Aptose Biosciences, Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE...
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
May 31, 2022 16:15 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd
May 25, 2022 08:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd
May 12, 2022 10:00 ET
|
Aptose Biosciences, Inc.
Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th at EHA2022 Hybrid Congress SAN DIEGO and TORONTO, May 12, 2022 (GLOBE NEWSWIRE) --...
Aptose Reports Results for the First Quarter 2022
May 09, 2022 16:01 ET
|
Aptose Biosciences, Inc.
Expands HM43239 dose cohort at 160 mg Headway with luxeptinib “G3” formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and TORONTO, May 09, 2022 (GLOBE NEWSWIRE) --...
Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
May 04, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference
May 03, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation
May 02, 2022 16:10 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022
April 25, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase...